Search

Your search keyword '"Lotan Y"' showing total 1,295 results

Search Constraints

Start Over You searched for: Author "Lotan Y" Remove constraint Author: "Lotan Y"
1,295 results on '"Lotan Y"'

Search Results

1. The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States

2. Natural history of cN+ bladder cancer treated with radical cystectomy with or without perioperative treatment

3. The optimal number of induction chemotherapy cycles in cN+ bladder cancer

4. Molecular subtyping for predicting non-organ confined disease and survival outcomes after radical cystectomy in clinical high-grade T1 and T2 bladder cancer patients

5. Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial

6. Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium

8. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

9. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.

10. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

12. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma

13. Corrigendum to “Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium” [Eur Urol Focus 2021;7:1347–54]

21. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer

22. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)

24. Prognostic impact of perioperative circulating levels of Insulin-like growth factor-I (IGF-I) and its binding proteins, IGFBP-2 and IGFBP-3, on disease outcomes after radical cystectomy

28. Quality Metric to Assess Adequacy of Hydrogel Rectal Spacer Placement for Prostate Radiotherapy and Association of Metric Score With Dosimetric and Gastrointestinal Toxicity Outcomes

30. Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses

31. Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

32. Molecular characterization of residual bladder cancer after pembrolizumab

34. Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

35. Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy

36. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert(R) Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer

37. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

38. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria

39. Reply by Authors - Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer

40. Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis

46. Apport de la radiomique pour prédire la récidive après résection chirurgicale d’un carcinome rénal à cellules claires à haut risque

47. Signature pathomique comme indicateur pronostique dans le carcinome rénal à cellules claires

49. Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)

50. Blue light cystoscopy for detection of invasive bladder tumor: Results from multi-institutional registry

Catalog

Books, media, physical & digital resources